Sanjay Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sanjay Sharma has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Ketan Hatware
Department of Life Sciences, School of Pharmacy, IMU University,Kuala Lumpur, Malaysia
5 shared publications - Kiran Patil
NMIMS, School of Pharmacy and Technology Management, Shirpur, Maharashtra, India
5 shared publications - Deepak Choudhary
Department of Pharmaceutical Sciences, Mohanlal Sukhadia University, Udaipur, India
4 shared publications - Nandan Godani
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, Deemed to beUniversity, Vile Parle West, Mumbai, Maharashtra, 400056, India
3 shared publications - Saradhkumar Mudaliar
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, Deemed to beUniversity, Vile Parle West, Mumbai, Maharashtra, 400056, India
3 shared publications Sravani Karri
NMIMS, School of Pharmacy and Technology Management, Shirpur, Maharashtra, India
3 shared publications
Latest Publications
- 26 August 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 22 (1) , 117
Comparative Analysis of Regulatory Approaches for Artificial Intelligence Enabled Combination Devices in the United States, Europe, and Japan
- 26 August 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 22 (1) , 117
Comparative Analysis of Regulatory Approaches for Artificial Intelligence Enabled Combination Devices in the United States, Europe, and Japan
- 26 May 2026
- Published by Springer Nature in The Journal of Antibiotics
- Vol. 79 (7) , 425-436
Aztreonam–avibactam at the frontline: A dual-agent approach to metallo-β-lactamase resistance
Metallo-β-lactamase (MBL)–producing Gram-negative bacteria pose a significant problem to antibiotic treatment due to their ability to inactivate most β-lactam antibiotics and resist inhibition by conventional β-lactamase inhibitors. While aztreonam–avibactam (ATM–AVI) has proven to be an effective treatment for these bacteria, previous reviews have been largely narrative, either from a microbiological perspective or a clinical perspective in isolation. This review seeks to provide a mechanism-based and translational synthesis of ATM–AVI by combining molecular antibiotic science, pharmacokinetic/pharmacodynamic (PK/PD) concepts, antimicrobial susceptibility testing, and clinical data. The mechanism of action of ATM–AVI is based on the natural stability of aztreonam to MBLs, resistance to co-produced serine β-lactamases by avibactam, and appropriate exposure strategies to ensure target attainment. There is consistent activity against MBL-producing Enterobacterales and Pseudomonas aeruginosa in surveillance and clinical trials, but emerging resistance due to PBP3 insertions, porin mutations, and efflux pump overexpression identifies important biological targets. The future clinical utility of ATM–AVI will depend on mechanism-based susceptibility testing, rapid diagnostic integration, and stewardship-driven use, particularly in high-prevalence settings. Beyond its current clinical utility, ATM–AVI provides insight into principles for the rational development and responsible use of next-generation antibiotics in the face of complex resistance.
- 26 May 2026
- Published by Springer Nature in The Journal of Antibiotics
- Vol. 79 (7) , 425-436
Aztreonam–avibactam at the frontline: A dual-agent approach to metallo-β-lactamase resistance
Metallo-β-lactamase (MBL)–producing Gram-negative bacteria pose a significant problem to antibiotic treatment due to their ability to inactivate most β-lactam antibiotics and resist inhibition by conventional β-lactamase inhibitors. While aztreonam–avibactam (ATM–AVI) has proven to be an effective treatment for these bacteria, previous reviews have been largely narrative, either from a microbiological perspective or a clinical perspective in isolation. This review seeks to provide a mechanism-based and translational synthesis of ATM–AVI by combining molecular antibiotic science, pharmacokinetic/pharmacodynamic (PK/PD) concepts, antimicrobial susceptibility testing, and clinical data. The mechanism of action of ATM–AVI is based on the natural stability of aztreonam to MBLs, resistance to co-produced serine β-lactamases by avibactam, and appropriate exposure strategies to ensure target attainment. There is consistent activity against MBL-producing Enterobacterales and Pseudomonas aeruginosa in surveillance and clinical trials, but emerging resistance due to PBP3 insertions, porin mutations, and efflux pump overexpression identifies important biological targets. The future clinical utility of ATM–AVI will depend on mechanism-based susceptibility testing, rapid diagnostic integration, and stewardship-driven use, particularly in high-prevalence settings. Beyond its current clinical utility, ATM–AVI provides insight into principles for the rational development and responsible use of next-generation antibiotics in the face of complex resistance.
- 16 April 2026
- Published by Elsevier in Clinica Chimica Acta
- Vol. 589, 121008
Cortisol as a stress biomarker: analytical perspectives and challenges
- 16 April 2026
- Published by Elsevier in Clinica Chimica Acta
- Vol. 589, 121008
Cortisol as a stress biomarker: analytical perspectives and challenges
- 27 February 2026
- Published by Springer Nature in Journal of Applied Spectroscopy
- Vol. 93 (1) , 150-157
Eco-Friendly UV Spectroscopic Method for Precise Quantification of Daprodustat in Pharmaceuticals
- 27 February 2026
- Published by Springer Nature in Journal of Applied Spectroscopy
- Vol. 93 (1) , 150-157
Eco-Friendly UV Spectroscopic Method for Precise Quantification of Daprodustat in Pharmaceuticals
- 11 February 2026
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- p. 1-15
From black box to clear box: explainable AI for next-gen pharmacovigilance
Pharmacovigilance (PV) plays a vital role in post-marketing surveillance of drug safety; however, traditional methods are hindered by underreporting, data heterogeneity, and delayed signal detection. Artificial Intelligence (AI) has been increasingly employed to overcome these shortcomings through automation, advanced pattern recognition, and multimodal fusion of patient data. The regulatory acceptance of these systems rests on explainability, transparency, and auditability, which necessitate the inclusion of explainable AI (XAI) methods. This review thoroughly examines the international regulatory environment for AI in PV and suggests using Shapley Additive Explanations (SHAP) and Local Interpretable Model-Agnostic Explanations (LIME) to build regulatory trust. Research materials, including official guidelines and publications, were systematically sourced from authoritative regulatory websites in the US, Europe, and India, as well as from major academic databases such as Google Scholar, ScienceDirect, and PubMed. The EU AI Act classifies PV algorithms as 'high-risk,' imposing strict requirements for human oversight and transparency, aligning with the FDA's GMLP and India's Responsible AI principles. The review emphasizes traceability and governance, recommending convergence with human oversight into a regulatory-fit XAI framework to maximize safety signal detection and foster international trust in AI-based decision-making.
- 11 February 2026
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- p. 1-15
From black box to clear box: explainable AI for next-gen pharmacovigilance
Pharmacovigilance (PV) plays a vital role in post-marketing surveillance of drug safety; however, traditional methods are hindered by underreporting, data heterogeneity, and delayed signal detection. Artificial Intelligence (AI) has been increasingly employed to overcome these shortcomings through automation, advanced pattern recognition, and multimodal fusion of patient data. The regulatory acceptance of these systems rests on explainability, transparency, and auditability, which necessitate the inclusion of explainable AI (XAI) methods. This review thoroughly examines the international regulatory environment for AI in PV and suggests using Shapley Additive Explanations (SHAP) and Local Interpretable Model-Agnostic Explanations (LIME) to build regulatory trust. Research materials, including official guidelines and publications, were systematically sourced from authoritative regulatory websites in the US, Europe, and India, as well as from major academic databases such as Google Scholar, ScienceDirect, and PubMed. The EU AI Act classifies PV algorithms as 'high-risk,' imposing strict requirements for human oversight and transparency, aligning with the FDA's GMLP and India's Responsible AI principles. The review emphasizes traceability and governance, recommending convergence with human oversight into a regulatory-fit XAI framework to maximize safety signal detection and foster international trust in AI-based decision-making.
- 1 February 2026
- Published by Bentham Science Publishers Ltd. in Current Analytical Chemistry
- Vol. 22 (2) , 185-198
Insights into the Chemistry, Pharmacokinetics and Analytical Techniques of Lobeglitazone: A Novel Anti-diabetic Drug
Objective: This review article aims to provide crucial insights related to the chemistry, pharmacology and analytical techniques associated with Lobeglitazone, a promising anti-diabetic molecule. Diabetes is a chronic ailment which hinders the normal functioning of beta pancreatic cells due to which the pancreas becomes incapable of producing sufficient amount of insulin or the body is not able to utilize the insulin that is produced by the beta-pancreatic cells. Lobeglitazone is a novel thiazolidinedione class of drug approved for type-II diabetes management by regulatory agencies in South Korea and India. The molecule has the potential to replace pioglitazone for the treatment of type-II diabetes due to its lower effective dose (0.5 mg) and better safety profile. Method: A comprehensive literature review was conducted using sources like PubMed, ScienceDirect, and Google Scholar. The review focused on chemistry, pharmacology, efficacy, safety, and advancements in analytical techniques for Lobeglitazone estimation in biological samples, bulk, and dosage forms. Result: Lobeglitazone exhibits potent therapeutic efficacy in treating type-II diabetes with fewer adverse effects compared to previous thiazolidinedione drugs. It demonstrates a better safety profile, especially in terms of cardiovascular risk. However, current analytical methods for lobeglitazone rely on solvents that do not adhere to green chemistry principles, highlighting the need for eco-friendly alternatives. Conclusion: Lobeglitazone holds substantial potential to replace older thiazolidinedione drugs due to its lower effective dose and improved safety profile. Future research should focus on developing sustainable analytical methods that align with green chemistry principles, further reinforcing its role in diabetes management.
- 1 February 2026
- Published by Bentham Science Publishers Ltd. in Current Analytical Chemistry
- Vol. 22 (2) , 185-198
Insights into the Chemistry, Pharmacokinetics and Analytical Techniques of Lobeglitazone: A Novel Anti-diabetic Drug
Objective: This review article aims to provide crucial insights related to the chemistry, pharmacology and analytical techniques associated with Lobeglitazone, a promising anti-diabetic molecule. Diabetes is a chronic ailment which hinders the normal functioning of beta pancreatic cells due to which the pancreas becomes incapable of producing sufficient amount of insulin or the body is not able to utilize the insulin that is produced by the beta-pancreatic cells. Lobeglitazone is a novel thiazolidinedione class of drug approved for type-II diabetes management by regulatory agencies in South Korea and India. The molecule has the potential to replace pioglitazone for the treatment of type-II diabetes due to its lower effective dose (0.5 mg) and better safety profile. Method: A comprehensive literature review was conducted using sources like PubMed, ScienceDirect, and Google Scholar. The review focused on chemistry, pharmacology, efficacy, safety, and advancements in analytical techniques for Lobeglitazone estimation in biological samples, bulk, and dosage forms. Result: Lobeglitazone exhibits potent therapeutic efficacy in treating type-II diabetes with fewer adverse effects compared to previous thiazolidinedione drugs. It demonstrates a better safety profile, especially in terms of cardiovascular risk. However, current analytical methods for lobeglitazone rely on solvents that do not adhere to green chemistry principles, highlighting the need for eco-friendly alternatives. Conclusion: Lobeglitazone holds substantial potential to replace older thiazolidinedione drugs due to its lower effective dose and improved safety profile. Future research should focus on developing sustainable analytical methods that align with green chemistry principles, further reinforcing its role in diabetes management.
- 18 December 2025
- Published by Elsevier in Annales Pharmaceutiques Françaises
- Vol. 84 (3) , 442-453
Comparative study of regulatory frameworks for medicinal products in Eurasian Economic Union and European Union
- 18 December 2025
- Published by Elsevier in Annales Pharmaceutiques Françaises
- Vol. 84 (3) , 442-453
Comparative study of regulatory frameworks for medicinal products in Eurasian Economic Union and European Union